drugset / Trial / NCT03646162
Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
RandomizedParallel-groupDouble-blindTreatment
Summary
Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate cancer
Timeline
- Start
- 2018-09-14
- Primary completion
- 2020-04-30
- Completion
- 2020-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Veru-944 | Unknown | 10 mg | Oral |
| Subject | Veru-944 | Unknown | 50 mg | Oral |
| Subject | Veru-944 | Unknown | 100 mg | Oral |